145 related articles for article (PubMed ID: 33444472)
21. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
23. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.
Le Bourgeois A; Labopin M; Marçais A; de Latour RP; Blaise D; Chantepie S; N'Guyen S; Maillard N; Forcade E; Yakoub-Agha I; Huynh A; Marchand T; Bilger K; Ceballos P; Charbonnier A; Turlure P; Rubio MT; Béné MC; Guillaume T; Mohty M; Chevallier P;
Ann Hematol; 2020 Aug; 99(8):1855-1862. PubMed ID: 32564196
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
26. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
[TBL] [Abstract][Full Text] [Related]
27. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.
Krakow EF; Gyurkocza B; Storer BE; Chauncey TR; McCune JS; Radich JP; Bouvier ME; Estey EH; Storb R; Maloney DG; Sandmaier BM
Am J Hematol; 2020 Jan; 95(1):48-56. PubMed ID: 31637757
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Li S; Dvorak CC; Lu Y; Chan D; Gobburu JVS; Long-Boyle J; Apsel Winger B
J Clin Pharmacol; 2022 Jul; 62(7):873-882. PubMed ID: 35048362
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Shah GL; Boelens JJ; Carlow D; Lin A; Schofield R; Cruz Sitner N; Alperovich A; Ruiz J; Proli A; Dahi P; Tamari R; Giralt SA; Scordo M; Admiraal R
Clin Pharmacokinet; 2022 Apr; 61(4):553-563. PubMed ID: 34859337
[TBL] [Abstract][Full Text] [Related]
32. Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.
Ben Hassine K; Powys M; Svec P; Pozdechova M; Versluys B; Ansari M; Shaw PJ
Front Pediatr; 2021; 9():775485. PubMed ID: 34956984
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
[TBL] [Abstract][Full Text] [Related]
34. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
[TBL] [Abstract][Full Text] [Related]
35. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
[TBL] [Abstract][Full Text] [Related]
36. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
37. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
Locke F; Agarwal R; Kunnavakkam R; van Besien K; Larson RA; Odenike O; Godley LA; Liu H; Le Beau MM; Gurbuxani S; Thirman MJ; Sipkins D; White C; Artz A; Stock W
Bone Marrow Transplant; 2013 Nov; 48(11):1437-43. PubMed ID: 23771005
[TBL] [Abstract][Full Text] [Related]
38. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.
Langenhorst JB; van Kesteren C; van Maarseveen EM; Dorlo TPC; Nierkens S; Lindemans CA; de Witte MA; van Rhenen A; Raijmakers R; Bierings M; Kuball J; Huitema ADR; Boelens JJ
Blood Adv; 2019 Jul; 3(14):2179-2187. PubMed ID: 31324638
[TBL] [Abstract][Full Text] [Related]
40. Predictive Value of C-Reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Takahashi T; Jaber MM; Smith AR; Jacobson PA; Fisher J; Kirstein MN
J Clin Pharmacol; 2022 Jul; 62(7):855-862. PubMed ID: 34970774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
